Background
Understanding how HIV contributes to excess cardiovascular disease (CVD) risk beyond traditional CVD risk factors is important to identify interventions to reduce CVD risk for people with HIV (PWH). Microbiome dependent metabolites may represent novel modifiable biomarkers of CVD risk PWH. Alterations in gut microbial composition may affect the production of microbiome dependent metabolites like trimethylamine N-oxide (TMAO), which are associated with increased atherosclerotic CVD risk in people without HIV. In PWH, sparse conflicting data limit knowledge about TMAO and incident clinical CVD events and whether these relationships persist independently of HIV suppression and renal dysfunction that may limit TMAO clearance from circulation.
Methods
Among Veterans Aging Cohort Study – HIV Biomarker cohort participants, we assessed TMAO with Ultra-high Performance Liquid Chromatography–Tandem Mass Spectrometry and incident CVD events using ICD9 and ICD10 diagnostic codes for myocardial infarction, ischemic stroke, congestive heart failure (CHF), and coronary revascularization. We used Cox proportional hazards regression to estimate the association of TMAO and CVD. TMAO was grouped using thresholds for CVD risk from non-HIV populations (<6.2 (referent group), 6.2-10, ≥10 uM). Models were adjusted for age, HIV-1 RNA, hepatitis C, diabetes, lipids, FIB-4 score, estimated glomerular filtration rate, smoking and alcohol use.
Results
Mean (SD) age was 53 (9) years and median (25th, 75th percentile) TMAO was 5 (3, 8) uM and similar by HIV status. Median follow-up time for CVD (N=2034, 66% PWH, 550 incident events) was 13 (7,14) years. Among PWH, TMAO≥10 uM was associated with increased CVD risk (HR [95% confidence interval, CI]: 1.57 [1.17, 2.10]). Among those without HIV, TMAO between 6.2-10 uM was associated with increased CVD risk (HR [95% CI]: 1.71 -1.21-2.40).
Conclusions
PWH with the highest levels of TMAO had increased CVD risk compared to those with the lowest levels. In people without HIV, increased CVD risk was only observed in those with intermediate TMAO levels (i.e., between 6.2-10 uM). Future work should examine whether HIV-specific TMAO risk thresholds exist for atherosclerotic CVD and CHF and how such thresholds may clarify drivers of excess CVD risk in PWH.